<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Chen S</submitter><funding>Fundamental Research Project of the Shenzhen Science and Technology Innovation Commission</funding><funding>Basic and Applied Basic Research Foundation of Guangdong Province</funding><pagination>391</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12282008</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Although both pre-clinical and clinical studies show promising outcomes, resulting in rapid growth of clinical trials of MSC-based therapies in recent years, the heterogeneity and therapeutic inconsistency of MSCs have severely hampered their clinical applications. Purifying homogenous MSC populations with enhanced specific functions represents one promising approach. We have demonstrated recently that the CD317&lt;sup>+&lt;/sup> MSCs have enhanced anti-inflammatory functions and improved therapeutic efficacy and consistency.&lt;h4>Methods&lt;/h4>In the current study, we performed both in vitro and in vivo investigations to delineate whether and how CD317 regulates the immune modulation function of MSCs.&lt;h4>Results&lt;/h4>Our data here indicate that the CD317 directly contributes to th</pubmed_abstract><journal>Stem cell research &amp; therapy</journal><pubmed_title>CD317 stabilizes TNFR1 and confers the anti-inflammatory functions of MSCs via NF-κB/TSG6 pathway.</pubmed_title><pmcid>PMC12282008</pmcid><funding_grant_id>20231120113324002</funding_grant_id><funding_grant_id>Applied Basic Research Foundation</funding_grant_id><funding_grant_id>Guangdong Basic</funding_grant_id><pubmed_authors>Yao L</pubmed_authors><pubmed_authors>Wen X</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Chen L</pubmed_authors><pubmed_authors>Wang X</pubmed_authors><pubmed_authors>Chen S</pubmed_authors><pubmed_authors>Xu J</pubmed_authors></additional><is_claimable>false</is_claimable><name>CD317 stabilizes TNFR1 and confers the anti-inflammatory functions of MSCs via NF-κB/TSG6 pathway.</name><description>&lt;h4>Background&lt;/h4>Although both pre-clinical and clinical studies show promising outcomes, resulting in rapid growth of clinical trials of MSC-based therapies in recent years, the heterogeneity and therapeutic inconsistency of MSCs have severely hampered their clinical applications. Purifying homogenous MSC populations with enhanced specific functions represents one promising approach. We have demonstrated recently that the CD317&lt;sup>+&lt;/sup> MSCs have enhanced anti-inflammatory functions and improved therapeutic efficacy and consistency.&lt;h4>Methods&lt;/h4>In the current study, we performed both in vitro and in vivo investigations to delineate whether and how CD317 regulates the immune modulation function of MSCs.&lt;h4>Results&lt;/h4>Our data here indicate that the CD317 directly contributes to th</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jul</publication><modification>2026-03-18T14:14:21.889Z</modification><creation>2025-08-24T03:05:24.78Z</creation></dates><accession>S-EPMC12282008</accession><cross_references><pubmed>40691615</pubmed><doi>10.1186/s13287-025-04527-8</doi></cross_references></HashMap>